Combination therapy with transarterial chemoembolization and interferon-α compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 8, 2009, Pages 1437-1444

  Li, Maoquan ^a   Lu, Chenhui ^a   Cheng, Jie ^a   Zhang, Jiaxing ^a   Cao, Chuanwu ^a   Xu, Jiahua ^a   Xu, Jichong ^a   Pan, Hui ^a   Zhong, Baoliang ^b   Tucker, Steven ^c   Wang, Daoyuan ^a  

^a TONGJI UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c Pacific Cancer Centre   (Singapore)

Author keywords

Hepatocellular carcinoma; Interferon ; Recurrence; Transarterial chemoembolization

Indexed keywords

2 (A PHENYLETHYLACETATE) 4 CARBOXYLTHIAZOLIDINE; ALPHA INTERFERON; CISPLATIN; INTERFERON ALPHA1B; PARACETAMOL; SINOGEN; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BRAIN DISEASE; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEPATITIS B VIRUS; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PAIN; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT CANCER; RECURRENT DISEASE; RISK REDUCTION; SURVIVAL RATE; VOMITING;

EID: 69049092776     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05863.x     Document Type: Article

References (40)

1. Yu SZ. Primary prevention of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1995 10 : 674 682.
2. Bruix J, Llovet JM. Hepatocellular carcinoma surveillance: who is the target population? Hepatology 2003 37 : 507 509.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002 35 : 519 524.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 362 : 1907 1917.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003 37 : 429 442.
6. Lin SM, Lin CJ, Lin CC et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma
7. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002 35 : 1164 1171.
8. Omata M, Tateishi R, Yoshida H et al. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004 127 (Suppl. 1) S159 66.
9. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005 129 : 122 130.
10. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006 131 : 461 469.
11. Simonetti RG, Liberati A, Angiolini C et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann. Oncol. 1997 8 : 117 136.
12. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002 359 : 1734 1739.
13. Belghiti J, Panis Y, Farges O et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann. Surg. 1992 214 : 114 117.
14. Collconi M, Buzzoni R, Bajetta E et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993 72 : 3196 3201.
15. Kardinal CG, Moertel CG, Wieand HS et al. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer 1993 71 : 2187 2190.
16. Sachs E, Di Bisceglie AM, Dusheiko GM et al. Treatment of hepatocellular carcinoma with recombinant leukocyte interferon: pilot study. Br. J. Cancer 1985 52 : 105 109.
17. Ikeda K, Saitoh S, Suzuki Y et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. A pilot study. Cancer 1998 82 : 827 835.
18. Lin SM, Sheen IS, Chien RN et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999 29 : 971 975.
19. Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J. Hepatol. 1996 24 : 141 147.
20. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects on interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 346 : 1051 1055.
21. Kubo S, Nishiguchi S, Hirohashi K et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. 2001 134 : 963 967.
22. Ikeda K, Arase Y, Saitoh S et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000 32 : 228 232.
23. Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. 2003 138 : 299 306.
24. Oon CJ. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother. Pharmacol 1992 31S : S137 42.
25. Lin SM, Lin CJ, Hsu CW et al. Prospective randomized controlled study of interferonalpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004 100 : 376 382.
26. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985 56 : 918 928.
27. Kasugai H, Kojima J, Tatsuta M et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989 97 : 965 971.
28. Bartolozzi C, Lencioni R, Caramella D et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995 197 : 812 818.
29. Raoul JL, Guyader D, Bretagne JF et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997 26 : 1156 1161.
30. Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998 27 : 1578 1583.
31. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control. Clin. Trials. 1990 11 : 116 128.
32. Ikeda K, Arase Y, Kobayashi M et al. Hepatitis B virus-related hepatocellular carcinogenesis and its prevention. Intervirology 2005 48 : 29 38.
33. van der Eijk AA, Niesters HG, Hansen BE et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBeantigen positive hepatitis B patients treated with interferon-alpha. J. Viral. Hepat. 2006 13 : 96 103.
34. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004 127 : S303 9.
35. Truong BX, Seo Y, Kato M et al. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int. J. Mol. Med. 2005 16 : 279 284.
36. Jang JW, Choi JY, Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J. Hepatol. 2004 41 : 427 435.
37. Kubo S, Nishiguchi S, Hirohashi K et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br. J. Surg. 2002 89 : 418 422.
38. Sun HC, Tang ZY, Wang L et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J. Cancer. Res. Clin. Oncol. 2006 132 : 458 465.
39. Lo CM, Liu CL, Chan SC et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann. Surg. 2007 245 : 831 842.
40. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001 6 : 34 55.